232P - Circulating tumor cells as an early predictive marker of disease progression in metastatic breast cancer patients

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer
Presenter Samy Algizawy
Citation Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365
Authors S.M. Algizawy1, H.H. Essa1, E. El-Gezawy2, N.N. Omar3, D.M. Sayed4
  • 1Clinical Oncology, Assiut University Hospitals, 71516 - Assiut/EG
  • 2Clinical Pathology, Assiut University Hospitals, 7111 - Assiut/EG
  • 3Radiology, Assiut University Hospitals, Assiut/EG
  • 4Clinical Pathology, South Egypt Cancer Institute SECI Assiut University, Assiut/EG

Abstract

Background

Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but their predictive value to monitor treatment efficacy still needs further investigation. The aim of this study was to test whether persistent elevation of circulating tumor cells (CTCs) at both baseline and before 2nd cycle of a new treatment can serve as an early predictive marker of disease progression in patients with metastatic breast cancer using the predefined 5 CTC/7.5 ml threshold.

Methods

Eighty-five patients with stage IV breast cancer who met the eligibility criteria were enrolled in the study. Before starting a new treatment, all patients underwent full imaging studies and blood sampling for CTC enumeration. Patients with 

Results

At baseline, 44 (51.8%) of the 85 eligible patients did not have increased CTC levels. Of the other 41 patients with ≥ 5 CTCs /7.5 ml blood, only 38 patients had CTCs evaluation at first follow-up before 2nd cycle (CTCFU) that showed 25 (65.8 %) patients had 

Conclusions

This study supports the significance of elevated CTCs before C2 in MBC patients starting a new line of chemotherapy as an early predictive marker of disease progression, thus, monitoring treatment benefit. It confirmed the independent prognostic significance of CTCs.

Clinical trial identification

not applicable, no trial protocol number

Legal entity responsible for the study

The Ethics Committee of the Faculty of Medicine, Assiut University

Funding

Assiut University Hospitals

Disclosure

All authors have declared no conflicts of interest.